|Awarded On||August 17, 2016|
|Title||School-Based Human Papillomavirus Vaccination Program in the Lower Rio Grande Valley|
|Award Mechanism||Evidence-Based Prevention Programs and Services|
|Institution/Organization||The University of Texas Medical Branch at Galveston|
|Principal Investigator/Program Director||Ana Rodriguez|
|Cancer Sites||Cervix Uteri|
The HPV vaccine reduces the morbidity and mortality of HPV-related diseases, including anogenital warts and cervical, oropharyngeal, vulvar, vaginal, penile, and anal cancer.[1-9] Guidelines recommend HPV vaccination for girls and boys aged 11–12, with catch-up doses for ages 13–26.[7,9]
We will use the 9-valent HPV vaccine, which covers 5 additional HPV cancer-causing types and is estimated to prevent 15% more cervical cancer than the quadrivalent vaccine. The 3-injection HPV vaccine series has to be given in early adolescence to maximize effectiveness. It provides the greatest benefit to adolescents before they become sexually active. The Healthy People 2020 goal is to vaccinate ...